CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP® Technology in anti-tumor cell therapies

  • CARISMA receives full rights to use the CAP® Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications
  • CEVEC’s unique CAP® cells are specifically designed for highly scalable, RCA-free adenoviral vector manufacturing in suspension bioreactors
  • The agreement supports CARISMA’s development of novel CAR-macrophage immunotherapies, a first-of-its-kind approach to the treatment of solid tumors

Cologne, Germany and Philadelphia, PA, February 2, 2021


Subscribe for the CEVEC Newsletter according to our Privacy Policy to receive the latest CEVEC News, including Press Releases, Conference Information and Webinar Invitations.

© CEVEC Pharmaceuticals GmbH 2020